Mr. Carlo Bellini
Carlo Bellini is President at Klox and has served as a member of our board of directors since April 2009. Mr. Bellini previously served as Managing Director of Vitus Capital Holdings Ltd., a private U.K. fund, from June 2011 to September 2014. He served as President of Domodimonti Srl, an Italian agricultural company, between April 2009 and June 2011. Prior to 2009, Mr. Bellini worked in different capacities at a variety of funds. Mr. Bellini received his Bachelor of Arts in Finance from McGill University.
Mr. Joseph D'Abramo
Mr. Joseph D’Abramo, CPA, CA, has been at Klox Technologies Inc. since 2014. Prior to joining the company, Mr. D’Abramo worked at Deloitte whereby he spent almost 10 years of his career attaining the rank of Senior Manager in the Assurance & Advisory group. He specialized in serving both large public and private entities, mainly in the technology sector, and has extensive industry knowledge of accounting and financial reporting, financial planning & analysis and corporate finance. Mr. D’Abramo holds a Bachelor of Commerce in Accounting and a Graduate Diploma in Chartered Accountancy from the John Molson School of Business in Montreal, Canada.
Dr. Lise Hébert
Lise Hébert, PhD has served as a member of our board of directors since April 2009. Prior to joining our company, Dr. Hébert served as vice president of Corporate Communications at Bellus Health Inc., a biotechnology company, for over 10 years. She currently serves on the Life Sciences Committee of the Fédération des Chambres du Commerce du Québec.
Dr. Hébert holds a PhD in Experimental Medicine from McGill University, where her research focused on amyloidosis and during which time she also conducted research at New York University Medical School. Dr. Hébert completed her post-doctoral studies at the Lady Davis Research Institute at the Montreal Jewish General Hospital and is the author of several patents.
Dr. Michael Nielsen
Associate professor from the Danish Technical University, DTU and Copenhagen University with a collaborative PhD from Tokyo University, Japan.
With a key focus on cellular biology, immunology and applied science collaborations, Dr. Nielsen is responsible for developing the technological platform of Kleresca® through research and studies. Dr. Nielsen is based in Denmark and Italy.
Mr. Mikkel Schødt
Highly experienced within the medical sector, Mr. Schoedt has worked as a consultant for medical/high tech companies and has led turn-arounds in Coloplast and LEO Pharma. Experience in building businesses in Denmark and the US within cardiology, neurology, and venerology.
A medical biochemist by education, Mr. Schoedt also has research experience from Novo Nordisk. Mr. Schoedt is based in Denmark.